PT3366688T - Substituted pyrazolopyrimidines as glucocerebrosidase activators - Google Patents

Substituted pyrazolopyrimidines as glucocerebrosidase activators

Info

Publication number: PT3366688T
Authority: PT; Portugal
Prior art keywords: substituted pyrazolopyrimidines; glucocerebrosidase; activators; glucocerebrosidase activators; pyrazolopyrimidines
Prior art date: 2010-12-08

Application number

PT181650052T

Other languages

Portuguese (pt)

Original Assignee

Us Health

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-08

Filing date

2011-12-08

Publication date

2022-05-11

2011-12-08 Application filed by Us Health filed Critical Us Health

2022-05-11 Publication of PT3366688T publication Critical patent/PT3366688T/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

PT181650052T 2010-12-08 2011-12-08 Substituted pyrazolopyrimidines as glucocerebrosidase activators PT3366688T (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42094610P	2010-12-08	2010-12-08

Publications (1)

Publication Number	Publication Date
PT3366688T true PT3366688T (en)	2022-05-11

Family

ID=45498099

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT181650052T PT3366688T (en)	2010-12-08	2011-12-08	Substituted pyrazolopyrimidines as glucocerebrosidase activators
PT118107143T PT2649075T (en)	2010-12-08	2011-12-08	Substituted pyrazolopyrimidines as glucocerebrosidase activators

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT118107143T PT2649075T (en)	2010-12-08	2011-12-08	Substituted pyrazolopyrimidines as glucocerebrosidase activators

Country Status (24)

Country	Link
US (3)	US9353117B2 (en)
EP (2)	EP2649075B1 (en)
JP (1)	JP6154746B2 (en)
KR (1)	KR101931224B1 (en)
CN (1)	CN103534255B (en)
AU (1)	AU2011338377B2 (en)
BR (1)	BR112013014242B1 (en)
CA (1)	CA2820362C (en)
CY (1)	CY1125186T1 (en)
DK (2)	DK2649075T3 (en)
ES (2)	ES2912284T3 (en)
HR (1)	HRP20220512T1 (en)
HU (1)	HUE038635T2 (en)
IL (2)	IL226767B (en)
LT (1)	LT3366688T (en)
MX (2)	MX354506B (en)
PL (2)	PL2649075T3 (en)
PT (2)	PT3366688T (en)
RS (1)	RS63320B1 (en)
RU (1)	RU2603637C2 (en)
SI (2)	SI2649075T1 (en)
TR (1)	TR201810523T4 (en)
WO (1)	WO2012078855A1 (en)
ZA (1)	ZA201304215B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL2649075T3 (en)	2010-12-08	2018-09-28	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2012177997A1 (en)	2011-06-22	2012-12-27	The General Hospital Corporation	Treatment of proteinopathies
JP2014517079A (en)	2011-06-22	2014-07-17	バーテックスファーマシューティカルズインコーポレイテッド	Compounds useful as ATR kinase inhibitors
PH12013502611A1 (en)	2011-06-24	2014-04-28	Amgen Inc	Trpm8 antagonists and their use in treatments
MX2013015058A (en)	2011-06-24	2014-01-20	Amgen Inc	Trpm8 antagonists and their use in treatments.
BR112014009531A8 (en) *	2011-10-20	2018-01-16	Glaxosmithkline Llc	substituted bicyclic azaheterocycles and analogues as sirtuin modulators
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US8952009B2 (en)	2012-08-06	2015-02-10	Amgen Inc.	Chroman derivatives as TRPM8 inhibitors
PL3486245T3 (en)	2012-12-07	2021-11-08	Vertex Pharmaceuticals Incorporated	2-amino-n-(piperidin-1-yl-pyridin-3-yl) pyrazolo[1,5alpha]pyrimidine-3-carboxamid as inhibitor of atr kinase
WO2014143240A1 (en)	2013-03-15	2014-09-18	Vertex Pharmaceuticals Incorporated	Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8969360B2 (en)	2013-03-15	2015-03-03	Vertex Pharmaceuticals Incorporated	Compounds useful as inhibitors of ATR kinase
EP2970289A1 (en)	2013-03-15	2016-01-20	Vertex Pharmaceuticals Inc.	Compounds useful as inhibitors of atr kinase
WO2015051241A1 (en)	2013-10-04	2015-04-09	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PH12016500582B1 (en)	2013-10-04	2023-06-30	Infinity Pharmaceuticals Inc	Heterocyclic compounds and uses thereof
DK3077397T3 (en)	2013-12-06	2019-12-16	Vertex Pharma	2-AMINO-6-FLUOR-N- [5-FLUOR-PYRIDIN-3-YL] PYRAZOLO [1,5-A] PYRIMIDIN-3-CARBOXAMIDE COMPOUND USED AS AN AT-KINASE INHIBITOR, DIFFERENTLY DIFFERENTLY DERIVATIVES THEREOF
JP6701088B2 (en)	2014-03-19	2020-05-27	インフィニティーファーマシューティカルズ，インコーポレイテッド	Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
CA2950587C (en)	2014-06-05	2022-06-28	Vertex Pharmaceuticals Incorporated	Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof
US11179394B2 (en)	2014-06-17	2021-11-23	Vertex Pharmaceuticals Incorporated	Method for treating cancer using a combination of Chk1 and ATR inhibitors
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CA2966259A1 (en)	2014-11-03	2016-05-12	Bayer Pharma Aktiengesellschaft	Piperidinylpyrazolopyrimidinones and their use
WO2016073889A1 (en)	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
US20180185368A1 (en)	2014-11-06	2018-07-05	Lysosomal Therapeutics Inc.	Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
WO2016073895A1 (en) *	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders
JP2018522872A (en) *	2015-07-01	2018-08-16	ノースウェスタンユニバーシティ	Substituted 4-methylpyrrolo [1,2-A] pyrimidine-8-carboxamide compounds and their use for modulation of glucocerebrosidase activity
EP3344625A4 (en) *	2015-09-04	2019-03-27	Lysosomal Therapeutics Inc.	Thiazolo(3,2-a) pyrimidinone and other heterobicyclic pyrimidinone compounds for use in medical therapy
US20190092789A1 (en) *	2015-09-04	2019-03-28	Lysosomal Therapeutics Inc.	Heterobicyclic pyrimidinone compounds and their use in the treatment of medical disorders
AU2016322552B2 (en)	2015-09-14	2021-03-25	Infinity Pharmaceuticals, Inc.	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
RU2768621C1 (en)	2015-09-30	2022-03-24	Вертекс Фармасьютикалз Инкорпорейтед	Method of treating cancer using a combination of dna damaging agents and atr inhibitors
EP3429590A4 (en) *	2016-03-16	2020-02-19	Lysosomal Therapeutics Inc.	Methods and compositions for treating a neurodegenerative disorder in a sphingotyped subject
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
JP7038063B2 (en) *	2016-04-06	2022-03-17	リソソーマル・セラピューティクス・インコーポレイテッド	Pyrazolo [1,5-a] pyrimidinylcarboxamide compounds and their use in the treatment of medical disorders
WO2017176961A1 (en) *	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Imidazo [1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
CA3020310A1 (en)	2016-04-06	2017-10-12	Lysosomal Therapeutics Inc.	Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
KR102530515B1 (en)	2016-05-05	2023-05-09	비알 - 알&디 인베스트먼츠, 에스.에이.	Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
EP3452480A4 (en) *	2016-05-05	2019-11-06	Lysosomal Therapeutics Inc.	Substituted pyrrolo[1,2- ]triazines and related compounds and their use in the treatment of medical disorders
EP3452455A4 (en) *	2016-05-05	2019-11-13	Lysosomal Therapeutics Inc.	Substituted imdazo[1,2- ]pyridines, substituted imidazo[1,2- ]pyrazines, related compounds, and their use in the treatment of medical disorders
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
WO2018083085A1 (en) *	2016-11-02	2018-05-11	F. Hoffmann-La Roche Ag	PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
ES2994013T3 (en) *	2017-07-28	2025-01-15	Takeda Pharmaceuticals Co	Tyk2 inhibitors and uses thereof
MX2020001261A (en)	2017-08-02	2020-08-17	Univ Northwestern	SUBSTITUTED FUSED PYRIMIDINE COMPOUNDS AND USES THEREOF.
AU2018346597B2 (en)	2017-10-06	2023-07-13	Forma Therapeutics, Inc.	Inhibiting Ubiquitin Specific Peptidase 30
JP7317721B2 (en)	2018-01-31	2023-07-31	武田薬品工業株式会社	heterocyclic compound
US12049466B2 (en)	2018-05-17	2024-07-30	Forma Therapeutics, Inc.	Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors
US10882865B2 (en)	2018-08-31	2021-01-05	Northwestern University	Pyrrolopyrimidine compounds and uses thereof for modulating glucocerebrosidase activity
ES2938751T3 (en)	2018-09-10	2023-04-14	Lilly Co Eli	Pyrazole[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
LT3860989T (en)	2018-10-05	2023-06-12	Forma Therapeutics, Inc.	FUSION PYROLINES THAT ACT AS INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 30 (UPS30)
EP3866789A4 (en) *	2018-10-15	2022-07-06	Nimbus Lakshmi, Inc.	TYK2 INHIBITORS AND THEIR USES
TWI800696B (en)	2018-12-10	2023-05-01	美商美國禮來大藥廠	7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
US20220332720A1 (en) *	2019-08-21	2022-10-20	The Scripps Research Institute	Bicyclic agonists of stimulator of interferon genes sting
CN114787135A (en)	2019-09-17	2022-07-22	比亚尔R&D投资股份公司	Substituted imidazole carboxamides and their use in the treatment of medical disorders
EP4031535A1 (en)	2019-09-17	2022-07-27	Bial-R&D Investments, S.A.	Substituted n-heterocyclic carboxamides as acid ceramidase inhibitors and their use as medicaments
US20220380314A1 (en)	2019-09-17	2022-12-01	Bial - R&D Investments, S.A.	Substituted, saturated and unsaturated n-heterocyclic carboxamides and related compounds for their use in the treatment of medical disorders
IL293409A (en) *	2019-11-25	2022-07-01	Gain Therapeutics Sa	Aryl and heteroaryl compounds, and their therapeutic uses in conditions related to changing the activity of galactocerebrosidase
AR121251A1 (en)	2020-02-12	2022-05-04	Lilly Co Eli	7-(METHYLAMINO)PYRAZOLE[1,5-A]PYRIMIDINE-3-CARBOXAMIDE COMPOUNDS

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2003284886A1 (en)	2002-10-21	2004-05-13	William E. Balch	CHEMICAL CHAPERONES AND THEIR EFFECT UPON THE CELLULAR ACTIVITY OF Beta-GLUCOSIDASE
JP2004277337A (en) *	2003-03-14	2004-10-07	Sumitomo Pharmaceut Co Ltd	Pyrazolo [1,5-a] pyrimidine derivatives
EP1615697A2 (en) *	2003-04-11	2006-01-18	Novo Nordisk A/S	New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof
EP1682134A4 (en)	2003-11-12	2008-10-15	Amicus Therapeutics Inc	Glucoimidazole and polyhydroxycyclohexenyl amine derivatives to treat gaucher disease
CA2507348C (en) *	2004-05-13	2013-07-16	The Hospital For Sick Children	Real time methylumbelliferone-based assay
WO2005113004A2 (en) *	2004-05-14	2005-12-01	The Cleveland Clinic Founfation	Small molecule inhibitors for mrp1 and other multidrug transporters
AU2005254657B2 (en)	2004-06-21	2011-03-17	F. Hoffmann-La Roche Ag	Pyrrazolo-pyrimidine derivatives
DE102005007534A1 (en) *	2005-02-17	2006-08-31	Bayer Cropscience Ag	pyrazolopyrimidine
US20070155737A1 (en)	2005-05-20	2007-07-05	Alantos Pharmaceuticals, Inc.	Heterobicyclic metalloprotease inhibitors
AU2006251989B2 (en)	2005-05-20	2010-05-27	Alantos-Pharmaceuticals, Inc.	Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
WO2007008541A2 (en)	2005-07-08	2007-01-18	Kalypsys, Inc.	Cellular cholesterol absorption modifiers
EP1917262B1 (en)	2005-08-15	2011-12-14	F. Hoffmann-La Roche AG	Piperidine and piperazine derivatives as p2x3 antagonists
KR101071438B1 (en) *	2005-10-21	2011-10-10	미쓰비시 타나베 파마 코퍼레이션	PYRAZOLO[1,5-ａ]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS
AU2006304875B2 (en) *	2005-10-21	2013-01-17	Exelixis, Inc.	Pyrazolo-pyrimidines as casein kinase II (CK2) modulators
WO2008054947A2 (en)	2006-10-02	2008-05-08	The Brigham And Women's Hospital, Inc.	Structure of acid beta-glucosidase and methods for identifying therapeutic agents
US20090275586A1 (en)	2006-10-06	2009-11-05	Kalypsys, Inc.	Heterocyclic inhibitors of pde4
AU2007321924A1 (en)	2006-11-20	2008-05-29	Alantos Pharmaceuticals Holding, Inc.	Heterobicyclic metalloprotease inhibitors
JP5586453B2 (en)	2007-04-13	2014-09-10	アミカスセラピューティックスインコーポレイテッド	Treatment of Gaucher disease with specific pharmacological chaperones and monitoring of treatment with surrogate markers
US20090215778A1 (en)	2007-04-27	2009-08-27	Panacos Pharmaceuticals, Inc.	Alpha-substituted Arylmethyl Piperazine Pyrazolo [1,5-alpha]Pyrimidine Amide Derivatives
HUE027278T2 (en)	2007-05-16	2016-11-28	Brigham & Womens Hospital Inc	Treatment of synucleinopathies
WO2008154207A1 (en)	2007-06-08	2008-12-18	The Burnham Institute For Medical Research	Methods and compounds for regulating apoptosis
JP5337405B2 (en)	2007-09-17	2013-11-06	ザ・ホスピタル・フォー・シック・チルドレン	How to treat Gaucher disease
WO2009049422A1 (en)	2007-10-18	2009-04-23	The Hospital For Sick Children	Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease
EP2219646A4 (en)	2007-12-21	2010-12-22	Univ Rochester	METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
EP2313411A1 (en) *	2008-06-10	2011-04-27	Plexxikon, Inc.	5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor
WO2010003023A2 (en) *	2008-07-01	2010-01-07	Zacharon Pharmaceuticals, Inc.	Heparan sulfate inhibitors
WO2010086040A1 (en) *	2009-01-29	2010-08-05	Biomarin Iga, Ltd.	Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
PL2649075T3 (en) *	2010-12-08	2018-09-28	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Substituted pyrazolopyrimidines as glucocerebrosidase activators
WO2016073895A1 (en) *	2014-11-06	2016-05-12	Lysosomal Therapeutics Inc.	Substituted pyrazolo(1,5-a)pyrimidines and their use in the treatment of medical disorders

2011
- 2011-12-08 PL PL11810714T patent/PL2649075T3/en unknown
- 2011-12-08 MX MX2013006462A patent/MX354506B/en active IP Right Grant
- 2011-12-08 US US13/991,816 patent/US9353117B2/en active Active
- 2011-12-08 EP EP11810714.3A patent/EP2649075B1/en active Active
- 2011-12-08 SI SI201131532T patent/SI2649075T1/en unknown
- 2011-12-08 SI SI201132052T patent/SI3366688T1/en unknown
- 2011-12-08 PT PT181650052T patent/PT3366688T/en unknown
- 2011-12-08 BR BR112013014242-1A patent/BR112013014242B1/en active IP Right Grant
- 2011-12-08 DK DK11810714.3T patent/DK2649075T3/en active
- 2011-12-08 CA CA2820362A patent/CA2820362C/en active Active
- 2011-12-08 EP EP18165005.2A patent/EP3366688B1/en active Active
- 2011-12-08 WO PCT/US2011/063928 patent/WO2012078855A1/en not_active Ceased
- 2011-12-08 PL PL18165005T patent/PL3366688T3/en unknown
- 2011-12-08 RU RU2013126094/04A patent/RU2603637C2/en active
- 2011-12-08 ES ES18165005T patent/ES2912284T3/en active Active
- 2011-12-08 LT LTEP18165005.2T patent/LT3366688T/en unknown
- 2011-12-08 TR TR2018/10523T patent/TR201810523T4/en unknown
- 2011-12-08 MX MX2018000385A patent/MX385600B/en unknown
- 2011-12-08 JP JP2013543335A patent/JP6154746B2/en active Active
- 2011-12-08 AU AU2011338377A patent/AU2011338377B2/en active Active
- 2011-12-08 KR KR1020137017520A patent/KR101931224B1/en active Active
- 2011-12-08 DK DK18165005.2T patent/DK3366688T3/en active
- 2011-12-08 HU HUE11810714A patent/HUE038635T2/en unknown
- 2011-12-08 PT PT118107143T patent/PT2649075T/en unknown
- 2011-12-08 CN CN201180066859.7A patent/CN103534255B/en active Active
- 2011-12-08 HR HRP20220512TT patent/HRP20220512T1/en unknown
- 2011-12-08 ES ES11810714.3T patent/ES2681218T3/en active Active
- 2011-12-08 RS RS20220422A patent/RS63320B1/en unknown
2013
- 2013-06-06 IL IL226767A patent/IL226767B/en active IP Right Grant
- 2013-06-07 ZA ZA2013/04215A patent/ZA201304215B/en unknown
2016
- 2016-04-28 US US15/141,275 patent/US9974789B2/en active Active
2018
- 2018-05-18 US US15/983,844 patent/US10925874B2/en active Active
- 2018-05-28 IL IL259648A patent/IL259648B/en active IP Right Grant
2022
- 2022-05-04 CY CY20221100316T patent/CY1125186T1/en unknown

Also Published As

Publication number	Publication date
US20180263988A1 (en)	2018-09-20
DK3366688T3 (en)	2022-05-02
AU2011338377A8 (en)	2015-10-29
LT3366688T (en)	2022-05-25
WO2012078855A1 (en)	2012-06-14
RU2603637C2 (en)	2016-11-27
MX354506B (en)	2018-01-16
EP3366688A1 (en)	2018-08-29
CN103534255B (en)	2016-12-21
PT2649075T (en)	2018-07-30
TR201810523T4 (en)	2018-08-27
AU2011338377A1 (en)	2013-07-04
CN103534255A (en)	2014-01-22
MX2013006462A (en)	2013-10-01
PL2649075T3 (en)	2018-09-28
KR101931224B1 (en)	2018-12-20
JP2013544893A (en)	2013-12-19
CY1125186T1 (en)	2024-12-13
BR112013014242B1 (en)	2022-02-22
EP2649075B1 (en)	2018-04-25
SI3366688T1 (en)	2022-07-29
IL226767B (en)	2018-06-28
JP6154746B2 (en)	2017-06-28
US9974789B2 (en)	2018-05-22
US20160346284A1 (en)	2016-12-01
PL3366688T3 (en)	2022-05-23
CA2820362A1 (en)	2012-06-14
CA2820362C (en)	2020-03-24
SI2649075T1 (en)	2018-10-30
EP3366688B1 (en)	2022-02-09
IL259648B (en)	2021-03-25
ES2912284T3 (en)	2022-05-25
HRP20220512T1 (en)	2022-05-27
DK2649075T3 (en)	2018-07-30
US9353117B2 (en)	2016-05-31
US10925874B2 (en)	2021-02-23
ZA201304215B (en)	2014-03-26
KR20140010012A (en)	2014-01-23
RU2013126094A (en)	2015-01-20
AU2011338377B2 (en)	2016-08-04
IL259648A (en)	2018-07-31
BR112013014242A2 (en)	2018-06-26
US20140249145A1 (en)	2014-09-04
RS63320B1 (en)	2022-07-29
EP2649075A1 (en)	2013-10-16
ES2681218T3 (en)	2018-09-12
HUE038635T2 (en)	2018-11-28
MX385600B (en)	2025-03-18

Publication	Publication Date	Title
IL259648A (en)	2018-07-31	Substituted pyrazolopyrimidines as glucocerebrosidase activators
AP3607A (en)	2016-02-26	Substituted imidazopyridazines
IL222646A0 (en)	2012-12-31	N3-substituted -n1-sulfonyl-5-fluoropyrimidinone derivatives
LT2534132T (en)	2017-07-10	Substituted pyrrolidine-2-carboxamides
ZA201209117B (en)	2013-09-25	Tetrahydro-pyrido-pyrimidine derivatives
EP2534256A4 (en)	2013-07-24	Novel uses
IL226192A0 (en)	2013-07-31	Substituted sodium-1h-pyrazole-5-olate
EP2541164A4 (en)	2016-09-07	Chiller
GB2490849B (en)	2020-01-01	Di-aspirin derivatives
IL225312A0 (en)	2013-06-27	Novel combinations
HUP1000243A2 (en)	2012-01-30	8-hidroxy-quinoline derivatives
AU4538P (en)	2013-05-16	H22 Grevillea juniperina
AU332681S (en)	2010-09-08	Spindle
GB201008355D0 (en)	2010-07-07	Solid supports
ZA201209248B (en)	2013-08-28	Amido-tropane derivatives
IL220983A0 (en)	2012-09-24	2-aldoximino-5-fluoropyrimidine derivatives
GB201019442D0 (en)	2010-12-29	Novel combinations
AU2010900285A0 (en)	2010-02-11	Sparger